efficacy of Oxcarbazepine and Phenytoin in control of epilepsy in the elderly
Phase 4
- Conditions
- Condition 1: epilepsy. Condition 2: epilepsy.Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizuresLocalization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
- Registration Number
- IRCT201202068943N1
- Lead Sponsor
- Vice-chancellor in Reaserch of Jondishapur University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 142
Inclusion Criteria
Age greater than 65 y/o; Not having acute treatable cause; Having secondary generalized epilepsy according to history and
Exclusion criteria: Previous history of reaction to phenytin or Oxcarbazepine; Having other causes except cerebrovascular disease as primary cause of epilepsy.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do Oxcarbazepine and Phenytoin modulate voltage-gated sodium channels in focal epilepsy of the elderly?
What are the primary outcomes of IRCT201202068943N1 comparing Oxcarbazepine and Phenytoin in elderly secondary generalized epilepsy?
Which genetic biomarkers predict response to Oxcarbazepine or Phenytoin in elderly patients with complex partial seizures?
What are the adverse event profiles and management strategies for Oxcarbazepine versus Phenytoin in geriatric epilepsy populations?
How does the efficacy of Oxcarbazepine and Phenytoin compare to other sodium channel blockers like Carbamazepine in elderly focal epilepsy?